Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 3/2018

01-03-2018 | Literatur kommentiert

Durvalumab verbessert die Prognose beim lokal fortgeschrittenen nicht-kleinzelligen Bronchialkarzinom nach definitiver Radiochemotherapie

Authors: Dr. med. Markus Hecht, Prof. Dr. Udo S Gaipl, Prof. Dr. med. Rainer Fietkau

Published in: Strahlentherapie und Onkologie | Issue 3/2018

Login to get access

Auszug

Bei 60–80 % der Patienten kommt es nach definitiver Radiochemotherapie (RCT) von lokal fortgeschrittenen nicht-kleinzelligen Bronchialkarzinomen (NSCLC) im weiteren Verlauf zum Progress. Eine Immuntherapie durch Inhibitoren des PD-1/PD-L1-Signalwegs ist in der Behandlung des metastasierten Bronchialkarzinoms bereits etabliert. In der hier kommentierten Studie wird die Wirksamkeit einer Erhaltungstherapie mit dem PD-L1-Antagonisten Durvalumab nach definitiver RCT beim lokal fortgeschrittenen NSCLC im Stadium III untersucht. …
Literature
1.
Flentje M, Huber RM, Engel-Riedel W et al (2016) GILT – A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer. Strahlenther Onkol 192:216–222CrossRefPubMed
2.
Reck M, Rodriguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Eng J Med 375:1823–1833CrossRef
3.
Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135CrossRefPubMedPubMedCentral
4.
Powles T, O’Donnell PH, Massard C et al (2017) Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. Jama Oncol 3:e172411CrossRefPubMed
5.
Dovedi SJ, Adlard AL, Lipowska-Bhalla G et al (2014) Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 74:5458–5468CrossRefPubMed
6.
Shaverdian N, Lisberg AE, Bornazyan K et al (2017) Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 18:895–903CrossRefPubMed
7.
Deng L, Liang H, Burnette B et al (2014) Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 124:687–695CrossRefPubMedPubMedCentral
8.
Ribeiro Gomes J, Schmerling RA, Haddad CK et al (2016) Analysis of the abscopal effect with anti-PD1 therapy in patients with metastatic solid tumors. J Immunother 39:367–372CrossRefPubMed
9.
Powell SR, Gitau MM, Sumey CJ et al (2017) Safety of pembrolizumab with chemoradiation (CRT) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). J Clin Oncol 35:6011CrossRef
Metadata
Title
Durvalumab verbessert die Prognose beim lokal fortgeschrittenen nicht-kleinzelligen Bronchialkarzinom nach definitiver Radiochemotherapie
Authors
Dr. med. Markus Hecht
Prof. Dr. Udo S Gaipl
Prof. Dr. med. Rainer Fietkau
Publication date
01-03-2018
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 3/2018
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-017-1253-3

Other articles of this Issue 3/2018

Strahlentherapie und Onkologie 3/2018 Go to the issue

Literatur kommentiert

Verbessertes Überleben beim fortgeschrittenen oder metastasierten Prostatakarzinom durch zusätzliches Abirateron zur initialen Androgendeprivation

Original Article

Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen

Original Article

Left-sided breast cancer and risks of secondary lung cancer and ischemic heart disease

Review Article

Essential role of radiation therapy for the treatment of pancreatic cancer

Original Article

Target tailoring and proton beam therapy to reduce small bowel dose in cervical cancer radiotherapy

Nachruf

Nachruf für Prof. Dr. med. Dr. hc. Wilhelm Oelßner, langjähriges Ehrenmitglied der DEGRO